ATE551060T1 - Zusammensetzungen und verfahren zur behandlung von neovaskulären erkrankungen - Google Patents
Zusammensetzungen und verfahren zur behandlung von neovaskulären erkrankungenInfo
- Publication number
- ATE551060T1 ATE551060T1 AT05804888T AT05804888T ATE551060T1 AT E551060 T1 ATE551060 T1 AT E551060T1 AT 05804888 T AT05804888 T AT 05804888T AT 05804888 T AT05804888 T AT 05804888T AT E551060 T1 ATE551060 T1 AT E551060T1
- Authority
- AT
- Austria
- Prior art keywords
- signaling inhibitor
- compositions
- methods
- neovascular diseases
- trprs
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
- A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/93—Ligases (6)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y601/00—Ligases forming carbon-oxygen bonds (6.1)
- C12Y601/01—Ligases forming aminoacyl-tRNA and related compounds (6.1.1)
- C12Y601/01002—Tryptophan-tRNA ligase (6.1.1.2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US57715604P | 2004-06-04 | 2004-06-04 | |
US58527304P | 2004-07-01 | 2004-07-01 | |
US65580105P | 2005-02-24 | 2005-02-24 | |
PCT/US2005/019800 WO2005117954A2 (en) | 2004-06-04 | 2005-06-06 | Compositions and methods for treatment of neovascular diseases |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE551060T1 true ATE551060T1 (de) | 2012-04-15 |
Family
ID=35463352
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT05804888T ATE551060T1 (de) | 2004-06-04 | 2005-06-06 | Zusammensetzungen und verfahren zur behandlung von neovaskulären erkrankungen |
Country Status (13)
Country | Link |
---|---|
US (2) | US7528106B2 (de) |
EP (3) | EP2484364B1 (de) |
JP (1) | JP4943324B2 (de) |
KR (1) | KR101224368B1 (de) |
AT (1) | ATE551060T1 (de) |
AU (1) | AU2005249586B2 (de) |
CA (1) | CA2568750C (de) |
DK (2) | DK2484365T3 (de) |
ES (3) | ES2382661T3 (de) |
MX (1) | MXPA06014092A (de) |
PL (2) | PL1765362T3 (de) |
PT (2) | PT2484365E (de) |
WO (1) | WO2005117954A2 (de) |
Families Citing this family (45)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7528106B2 (en) * | 2004-06-04 | 2009-05-05 | The Scripps Research Institute | Compositions and methods for treatment of neovascular diseases |
US20060024288A1 (en) * | 2004-08-02 | 2006-02-02 | Pfizer Inc. | tRNA synthetase fragments |
US8282921B2 (en) * | 2004-08-02 | 2012-10-09 | Paul Glidden | tRNA synthetase fragments |
BRPI0608272A2 (pt) * | 2005-02-24 | 2009-12-08 | Scripps Research Inst | método para promover revascularização fisiológica benéfica de tecido retinal isquêmico e método de triagem para identificar e avaliar a eficácia terapêutica de agentes terapêuticos potenciais para tratar doenças neovasculares retinais |
ES2338400B1 (es) * | 2008-05-06 | 2011-09-14 | David Benet Ferrus | Conjunto de moleculas antiangiogenicas y su uso. |
MX2010013632A (es) * | 2008-06-11 | 2011-06-16 | Atyr Pharma Inc | Actividad trombopoyetica de polipeptidos de tirosil-arnt sintetasa. |
CN106434576A (zh) | 2008-06-26 | 2017-02-22 | Atyr 医药公司 | 包含具有非常规生物活性的甘氨酰‑tRNA合成酶的组合物和方法 |
EP2403864B1 (de) | 2009-02-27 | 2015-08-12 | Atyr Pharma, Inc. | Polypeptidstrukturmotive im zusammenhang mit zellsignalisierungsaktivität |
ES2742251T3 (es) | 2009-03-16 | 2020-02-13 | Pangu Biopharma Ltd | Composiciones y procedimientos que comprenden variantes de splicing de histidil-tarn sintetasa que tienen actividades biológicas no canónicas |
US8661362B2 (en) * | 2009-03-16 | 2014-02-25 | Apple Inc. | Methods and graphical user interfaces for editing on a multifunction device with a touch screen display |
CA2757289A1 (en) * | 2009-03-31 | 2010-10-21 | Atyr Pharma, Inc. | Compositions and methods comprising aspartyl-trna synthetases having non-canonical biological activities |
US8828395B2 (en) | 2009-12-11 | 2014-09-09 | Atyr Pharma, Inc. | Antibodies that bind tyrosyl-tRNA synthetases |
EP2939689B1 (de) | 2009-12-11 | 2017-09-13 | aTyr Pharma, Inc. | Glutaminyl-TRNA-Synthetasen zur Verwendung zur Behandlung von Entzündungskrankheiten |
US20110150885A1 (en) * | 2009-12-11 | 2011-06-23 | Atyr Pharma, Inc. | Aminoacyl trna synthetases for modulating hematopoiesis |
WO2011139714A2 (en) | 2010-04-26 | 2011-11-10 | Atyr Pharma, Inc. | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of cysteinyl-trna synthetase |
CN103096911B (zh) | 2010-04-27 | 2018-05-29 | Atyr 医药公司 | 与异亮氨酰-tRNA合成酶的蛋白片段相关的治疗、诊断和抗体组合物的创新发现 |
ES2638311T3 (es) | 2010-04-27 | 2017-10-19 | Atyr Pharma, Inc. | Descubrimiento innovador de composiciones terapéuticas, diagnósticas y de anticuerpos relacionadas con fragmentos de proteína de treonil ARNt sintetasas |
WO2011139853A2 (en) | 2010-04-28 | 2011-11-10 | Atyr Pharma, Inc. | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of alanyl trna synthetases |
AU2011248457B2 (en) | 2010-04-29 | 2017-02-16 | Pangu Biopharma Limited | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of valyl tRNA synthetases |
WO2011150279A2 (en) | 2010-05-27 | 2011-12-01 | Atyr Pharma, Inc. | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of glutaminyl-trna synthetases |
CN103097523B (zh) | 2010-04-29 | 2016-09-28 | Atyr医药公司 | 与天冬酰胺酰-tRNA合成酶的蛋白片段相关的治疗、诊断和抗体组合物的创新发现 |
US8981045B2 (en) | 2010-05-03 | 2015-03-17 | Atyr Pharma, Inc. | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of methionyl-tRNA synthetases |
CN103108655B (zh) | 2010-05-03 | 2017-04-05 | Atyr 医药公司 | 与丝氨酰‑tRNA合成酶的蛋白片段相关的治疗、诊断和抗体组合物的创新发现 |
US8961961B2 (en) | 2010-05-03 | 2015-02-24 | a Tyr Pharma, Inc. | Innovative discovery of therapeutic, diagnostic, and antibody compositions related protein fragments of arginyl-tRNA synthetases |
CN105820252B (zh) | 2010-05-03 | 2020-07-21 | Atyr 医药公司 | 与苯丙氨酰-α-tRNA合成酶的蛋白片段相关的治疗、诊断和抗体组合物的创新发现 |
CA2798139C (en) | 2010-05-04 | 2019-09-24 | Atyr Pharma, Inc. | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of p38 multi-trna synthetase complex |
EP2566492B1 (de) | 2010-05-04 | 2016-10-26 | aTyr Pharma, Inc. | Innovative entdeckung therapeutischer zusammensetzungen im zusammenhang mit proteinfragmenten von glutamyl-prolyl-trna-synthetasen |
CN103200953B (zh) | 2010-05-14 | 2017-02-15 | Atyr 医药公司 | 与苯丙氨酰‑β‑tRNA合成酶的蛋白片段相关的治疗、诊断和抗体组合物的创新发现 |
AU2011256366C1 (en) | 2010-05-17 | 2017-06-15 | Pangu Biopharma Limited | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of leucyl-tRNA synthetases |
EP2575857B1 (de) | 2010-06-01 | 2018-01-24 | aTyr Pharma, Inc. | Innovative erkennung therapeutischer, diagnostischer und antikörperhaltiger zusammensetzungen in zusammenhang mit proteinfragmenten von lysyl-trna-synthetasen |
CN103124561B (zh) | 2010-07-12 | 2017-05-03 | Atyr 医药公司 | 与天冬氨酰‑tRNA合成酶的蛋白片段相关的治疗、诊断和抗体组合物的创新发现 |
US8999321B2 (en) | 2010-07-12 | 2015-04-07 | Atyr Pharma, Inc. | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of glycyl-tRNA synthetases |
US20130202576A1 (en) | 2010-07-12 | 2013-08-08 | Pangu Biopharma Limited | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of histidyl-trna synthetases |
AU2011289831C1 (en) | 2010-07-12 | 2017-06-15 | Pangu Biopharma Limited | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of glycyl-tRNA synthetases |
CN103108650A (zh) | 2010-08-25 | 2013-05-15 | Atyr医药公司 | 与酪氨酰-tRNA合成酶的蛋白片段相关的治疗、诊断和抗体组合物的创新发现 |
WO2012048125A2 (en) * | 2010-10-06 | 2012-04-12 | Atyr Pharma, Inc. | Innovative discovery of therapeutic, diagnostic, and antibody compositions related protein fragments of tryptophanyl trna synthetases |
US9714419B2 (en) | 2011-08-09 | 2017-07-25 | Atyr Pharma, Inc. | PEGylated tyrosyl-tRNA synthetase polypeptides |
US9822353B2 (en) | 2011-12-06 | 2017-11-21 | Atyr Pharma, Inc. | PEGylated aspartyl-tRNA synthetase polypeptides |
US9816084B2 (en) | 2011-12-06 | 2017-11-14 | Atyr Pharma, Inc. | Aspartyl-tRNA synthetases |
US9688978B2 (en) | 2011-12-29 | 2017-06-27 | Atyr Pharma, Inc. | Aspartyl-tRNA synthetase-Fc conjugates |
EP3311847A1 (de) | 2012-02-16 | 2018-04-25 | Atyr Pharma, Inc. | Histidyl-trna-synthetasen zur behandlung von autoimmun- und entzündungserkrankungen |
EP3460054B1 (de) | 2013-03-15 | 2020-10-21 | aTyr Pharma, Inc. | Histidyl-trna-synthetase-fc-konjugate |
WO2016137280A1 (ko) * | 2015-02-26 | 2016-09-01 | 재단법인 의약바이오컨버젼스연구단 | 트립토파닐 티알엔에이 합성효소를 유효성분으로 포함하는 감염성 염증 질환의 치료 또는 예방용 조성물 및 면역증강용 조성물 |
WO2018195338A1 (en) | 2017-04-20 | 2018-10-25 | Atyr Pharma, Inc. | Compositions and methods for treating lung inflammation |
WO2023001288A1 (zh) * | 2021-07-23 | 2023-01-26 | 百奥泰生物制药股份有限公司 | 整合素GPIIb/IIIa拮抗剂及其和抗VEGF抗体联合用药的应用 |
Family Cites Families (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE4405378A1 (de) | 1994-02-19 | 1995-08-24 | Merck Patent Gmbh | Adhäsionsrezeptor-Antagonisten |
US5753230A (en) | 1994-03-18 | 1998-05-19 | The Scripps Research Institute | Methods and compositions useful for inhibition of angiogenesis |
DE4415310A1 (de) | 1994-04-30 | 1995-11-02 | Merck Patent Gmbh | Cyclopeptide |
DE4429461A1 (de) | 1994-08-19 | 1996-02-22 | Merck Patent Gmbh | Adhäsionsrezeptor-Antagonisten |
ATE170179T1 (de) | 1994-11-02 | 1998-09-15 | Merck Patent Gmbh | Adhäsionsrezeptor-antagonisten |
DE19516483A1 (de) | 1995-05-05 | 1996-11-07 | Merck Patent Gmbh | Adhäsionsrezeptor-Antagonisten |
US5767071A (en) | 1995-06-07 | 1998-06-16 | Ixsys Incorporated | Sevenmer cyclic peptide inhibitors of diseases involving αv β3 |
US5780426A (en) | 1995-06-07 | 1998-07-14 | Ixsys, Incorporated | Fivemer cyclic peptide inhibitors of diseases involving αv β3 |
DE69738935D1 (de) * | 1996-11-05 | 2008-10-02 | Childrens Medical Center | Zusammensetzungen enthaltend Thalidomide und Dexamethason für die Behandlung von Krebs |
US6559144B2 (en) | 1997-02-13 | 2003-05-06 | Merck Patent Gesellschaft Mit | Bicyclic amino acids |
DE19705450A1 (de) * | 1997-02-13 | 1998-08-20 | Merck Patent Gmbh | Bicyclische aromatische Aminosäuren |
DE19755800A1 (de) | 1997-12-16 | 1999-06-17 | Merck Patent Gmbh | Cyclopeptidderivate |
DE19831710A1 (de) | 1998-07-15 | 2000-01-20 | Merck Patent Gmbh | Diacylhydrazinderivate |
EP1153014B1 (de) | 1999-02-20 | 2004-09-22 | MERCK PATENT GmbH | Beta-alaninderivate |
DE19916837A1 (de) | 1999-04-14 | 2000-10-19 | Merck Patent Gmbh | Dibenzoazulenderivate |
DE19932796A1 (de) | 1999-07-14 | 2001-01-18 | Merck Patent Gmbh | Diacylhydrazinderivate |
DE19939980A1 (de) | 1999-08-24 | 2001-03-01 | Merck Patent Gmbh | Inhibitoren des Integrins alphavbeta¶3¶ |
US20030017564A1 (en) * | 2001-02-23 | 2003-01-23 | Paul Schimmel | Tryptophanyl-tRNA synthetase derived polypeptides useful for the regulation of angiogenesis |
IL151940A0 (en) * | 2000-03-31 | 2003-04-10 | Scripps Research Inst | HUMAN AMINOACYL-tRNA SYNTHETASE POLYPETIDES USEFUL FOR THE REGULATION OF ANGIOGENESIS |
HUP0302718A3 (en) * | 2000-11-01 | 2011-03-28 | Merck Patent Gmbh | Methods and compositions for the treatment of diseases of the eye |
CA2427858A1 (en) * | 2000-11-03 | 2002-05-10 | University Of Vermont And State Agricultural College | Compositions for inhibiting grb7 |
UA75898C2 (en) * | 2000-11-14 | 2006-06-15 | Merck Patent Gmbh | Method for prophylaxis and treatment of eye diseases using antagonist of integrin receptors |
IL152420A0 (en) * | 2001-02-23 | 2003-05-29 | Novartis Ag | Novel oncolytic adenoviral vectors |
WO2003009813A2 (en) * | 2001-07-26 | 2003-02-06 | Novartis Ag | Methods of treating neuropilin-mediated diseases |
EP1441743A4 (de) * | 2001-11-09 | 2009-02-25 | Eyetech Pharmaceuticals | Verfahren zur behandlung von neovaskulären augenerkrankungen |
US20060193830A1 (en) * | 2002-03-20 | 2006-08-31 | Hauswirth William W | Raav vector compositions and methods for the treatment of choroidal neovascularization |
EP1501861A4 (de) * | 2002-05-06 | 2007-06-20 | Univ Texas | Gezielt bindende proteine zur verabreichung therapeutischer oder diagnostischer reagentien |
CN102813923B (zh) * | 2003-08-27 | 2015-04-01 | 奥普索特克公司 | 用于治疗眼新血管疾病的组合治疗 |
JP2007515966A (ja) * | 2003-12-23 | 2007-06-21 | ザ・トラスティーズ・オブ・ザ・ユニバーシティ・オブ・ペンシルバニア | 疾患の併用療法のための組成物および方法 |
US7528106B2 (en) * | 2004-06-04 | 2009-05-05 | The Scripps Research Institute | Compositions and methods for treatment of neovascular diseases |
-
2005
- 2005-06-06 US US11/145,587 patent/US7528106B2/en not_active Expired - Fee Related
- 2005-06-06 ES ES05804888T patent/ES2382661T3/es active Active
- 2005-06-06 AT AT05804888T patent/ATE551060T1/de active
- 2005-06-06 DK DK12002028.4T patent/DK2484365T3/da active
- 2005-06-06 DK DK05804888.5T patent/DK1765362T3/da active
- 2005-06-06 PT PT120020284T patent/PT2484365E/pt unknown
- 2005-06-06 AU AU2005249586A patent/AU2005249586B2/en not_active Ceased
- 2005-06-06 EP EP12002027.6A patent/EP2484364B1/de not_active Not-in-force
- 2005-06-06 ES ES12002027.6T patent/ES2450541T3/es active Active
- 2005-06-06 ES ES12002028.4T patent/ES2439390T3/es active Active
- 2005-06-06 KR KR1020077000238A patent/KR101224368B1/ko not_active IP Right Cessation
- 2005-06-06 EP EP12002028.4A patent/EP2484365B1/de not_active Not-in-force
- 2005-06-06 WO PCT/US2005/019800 patent/WO2005117954A2/en active Application Filing
- 2005-06-06 MX MXPA06014092A patent/MXPA06014092A/es active IP Right Grant
- 2005-06-06 PL PL05804888T patent/PL1765362T3/pl unknown
- 2005-06-06 EP EP05804888A patent/EP1765362B1/de not_active Not-in-force
- 2005-06-06 PT PT05804888T patent/PT1765362E/pt unknown
- 2005-06-06 CA CA2568750A patent/CA2568750C/en not_active Expired - Fee Related
- 2005-06-06 PL PL12002028T patent/PL2484365T3/pl unknown
- 2005-06-06 JP JP2007515675A patent/JP4943324B2/ja not_active Expired - Fee Related
-
2009
- 2009-05-04 US US12/387,507 patent/US20090285792A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
US7528106B2 (en) | 2009-05-05 |
EP1765362A2 (de) | 2007-03-28 |
JP2008501718A (ja) | 2008-01-24 |
DK1765362T3 (da) | 2012-05-14 |
EP2484364B1 (de) | 2014-02-19 |
PT1765362E (pt) | 2012-06-04 |
MXPA06014092A (es) | 2007-03-15 |
WO2005117954A3 (en) | 2006-10-12 |
JP4943324B2 (ja) | 2012-05-30 |
PL2484365T3 (pl) | 2014-03-31 |
DK2484365T3 (da) | 2013-12-02 |
KR20070041498A (ko) | 2007-04-18 |
ES2382661T3 (es) | 2012-06-12 |
AU2005249586A1 (en) | 2005-12-15 |
EP1765362A4 (de) | 2010-02-24 |
WO2005117954A2 (en) | 2005-12-15 |
EP1765362B1 (de) | 2012-03-28 |
EP2484364A1 (de) | 2012-08-08 |
ES2439390T3 (es) | 2014-01-22 |
KR101224368B1 (ko) | 2013-01-22 |
AU2005249586B2 (en) | 2010-12-23 |
ES2450541T3 (es) | 2014-03-25 |
US20090285792A1 (en) | 2009-11-19 |
CA2568750A1 (en) | 2005-12-15 |
US20060003933A1 (en) | 2006-01-05 |
EP2484365A1 (de) | 2012-08-08 |
PT2484365E (pt) | 2013-12-12 |
EP2484365B1 (de) | 2013-10-02 |
PL1765362T3 (pl) | 2012-08-31 |
CA2568750C (en) | 2014-05-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE551060T1 (de) | Zusammensetzungen und verfahren zur behandlung von neovaskulären erkrankungen | |
LTPA2017009I1 (lt) | Brutono tirozinkinazės inhibitoriai | |
WO2005063745A8 (en) | Novel spiroindoline or spiroisoquinoline compounds, methods of use and compositions thereof | |
DE60331537D1 (de) | Kombinationen zur behandlung von multiplem myelom | |
MXPA05013642A (es) | Composicion de un antagonista de vegf y un agente antiproliferativo y su uso para el tratamiento de cancer. | |
MX2007009960A (es) | Combinaciones y metodos de administracion de agentes terapeuticos y terapia de combinacion. | |
BRPI0408005A (pt) | composto, composição farmacêutica, métodos para inibir angiogênese, atividade de pde4 em uma célula e proliferação de célula de cáncer, para inibir ou reduzir polimerização de tubulina ou estabilidade de tubulina em uma célula, para tratar ou melhorar um distúrbio inflamatório, um cáncer e um distúrbio do sistema nervoso central e para visar, bloquear ou destruir a função de vasculatura de tumor e o endotélio de vasos de tumor | |
EA200970953A1 (ru) | СПЕЦИФИЧНЫЕ ИНГИБИТОРЫ PDGFRβ | |
ATE424208T1 (de) | Proteinkinaseinhibitoren | |
IL179206A0 (en) | Pyrrolylpyrimidine derivatives and pharmaceutical compositions containing the same | |
ATE419249T1 (de) | Inhibitoren von mitotischem kinesin | |
MX2007007027A (es) | Derivados piperazinilpiridina como agentes anti-obesidad. | |
EP1503748A4 (de) | Arzneimittel zur linderung durch taxan induzierte neurotoxizität | |
WO2006138589A3 (en) | Opioid receptor ligands | |
TW200603791A (en) | Compounds and compositions as cathepsin S inhibitors | |
ATE477021T1 (de) | 1,3,5-triazepin-dionen zur behandlung von malaria | |
GEP20125516B (en) | Therapeutic uses of inhibitors of rtp801 |